Healthcare
ZIVO Bioscience, Inc.(ZIVO)
Live Price
Offline$3.69
+0.00% today
1Y Change
-74.19%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +468.6%
- EPS Growth
- +14.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ZIVO Bioscience, Inc. (ZIVO) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $3.69 and down 74.2% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +468.6%, EPS growth of +14.8%, a dividend yield of 0.0%. What stands out right now is revenue +468.6%, EPS +14.8%, free cash flow +25.6% with operating margin -4045.7% and ROIC 342.8%. Valuation already assumes a fairly strong business story at price/sales 66.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZIVO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+468.6% vs +7.6% peer median
Operating Margin
Below sector median
-4045.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 15, 2026 with an EPS surprise of +20.0%.
The operating story is still moving forward
Revenue is running at +468.6% and EPS at +14.8%, with operating margin around -4045.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | +20.0% | +10.0% | +11.1% | โ |
2026 Feb 25, 2026 | +0.0% | -1.0% | -3.6% | -14.1% |
2025 Nov 14, 2025 | +0.0% | -2.9% | -34.7% | -26.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZIVO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZIVO Max Drawdown
-93.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZIVO and SPY.
Company Overview
ZIVO Bioscience, Inc.
Other OTC
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
- Leadership
- John Bernard Payne
- IPO Date
- Dec 15, 2003
- Employees
- 7
- Street Address
- 21 East Long Lake Road
- Mailing
- Bloomfield Hills, MI, 48304
- Region
- Bloomfield Hills, MI, US
- Reporting Currency
- USD
- Investor Line
- 248 452 9866
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 66.0
- Price/Book
- โ
Growth
- Revenue
- +468.6%
- EPS
- +14.8%
- Free Cash Flow
- +25.6%
Profitability
- Gross Margin
- 31.7%
- Operating Margin
- -4045.7%
- Net Margin
- -4059.7%
- ROE
- 426.5%
- ROIC
- 342.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.